Research programme: anti-obesity compounds - SIDR

Drug Profile

Research programme: anti-obesity compounds - SIDR

Alternative Names: Anti-obesity compounds research programme - SIDR

Latest Information Update: 05 Nov 2002

Price : $50

At a glance

  • Originator Strathclyde Institute for Drug Research
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 05 Nov 2002 Discontinued - Preclinical for Obesity in United Kingdom (unspecified route)
  • 01 Sep 2000 Ths programme is available for licensing (
  • 01 Sep 2000 Preclinical development for Obesity in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top